IP Library Granted Patent US 7,910,370
Granted Patent B2
US 7,910,370 · App. 11/869,634 · Granted Mar 22, 2011

Methods of using BCL-2 for the therapeutic treatment and prevention of diseases

Assignee: Sanford-Burnham Medical Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,370
App. No.
11/869,634
Granted
Mar 22, 2011
Kind
B2
Abstract

The invention provides a method of treating a disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. Also provided is a method of prolonging the in vivo survival of transplanted cells for the treatment of a disease or pathological condition. The method includes increasing the activity of Bcl-2 in a population of cells and transplanting the population of cells having increased Bcl-2 activity into a subject. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. A method to enhance the sensitivity of malignant cells to therapy is provided that includes decreasing the activity of Bcl-2 in the malignant cells. Methods to identify compounds that alter apoptotic cell death and to enhance monoclonal antibody production are also provided by the invention disclosed herein.

Claims (15)

1. A method of prolonging the survival of a β-cell from a pancreatic islet comprising increasing the activity of Bcl-2 in said β-cell, wherein increasing the activity of Bcl-2 in said β-cell comprises introducing and expressing in said β-cell a nucleic acid molecule encoding full length Bcl-2, Bcl-2/P59S or BHRF-1 and wherein introducing said nucleic acid molecule in said β-cell occurs in vitro, thereby prolonging the survival of said β-cell.

2. The method of claim 1 , wherein said nucleic acid molecule encodes human Bcl-2.

3. The method of claim 1 , wherein said nucleic acid molecule encodes Bcl-2/P59S.

4. The method of claim 1 , wherein said nucleic acid molecule encodes BHRF-1.

5. The method of claim 1 , further comprising introducing into said β-cell a nucleic acid encoding Raf-1.

6. The method of claim 1 , wherein said β-cells are human β-cells.

7. A method of prolonging the survival of transplanted β-cells, comprising increasing the activity of Bcl-2 in a population of β-cells from pancreatic islets and transplanting said population of β-cells having increased Bcl-2 activity into a subject, wherein increasing the activity of Bcl-2 in said population of β-cells comprises introducing and expressing in said β-cells a nucleic acid molecule encoding full length Bcl-2, Bcl-2/P59S or BHRF-1 and wherein introducing said nucleic acid molecule in said β-cell occurs in vitro.

8. The method of claim 7 , wherein said subject is a human.

9. The method of claim 7 , wherein said nucleic acid molecule encodes human Bcl-2.

10. The method of claim 7 , wherein said nucleic acid molecule encodes Bcl-2/P59S.

11. The method of claim 7 , wherein said nucleic acid molecule encodes BHRF-1.

12. The method of claim 7 , further comprising introducing into said cells a nucleic acid encoding Raf-1.

13. The method of claim 7 , wherein said β-cells are human β-cells.

14. The method of claim 7 , wherein said subject is diabetic.

15. The method of claim 7 , wherein said subject is insulin-dependent.

Assignments (4)
CONFIRMATORY LICENSE Recorded Aug 16, 2022
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 060814/0008 →
CHANGE OF NAME Recorded Feb 15, 2011
From: THE BURNHAM INSTITUTE
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 025810/0472 →
CHANGE OF NAME Recorded Feb 15, 2011
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 025812/0444 →
CHANGE OF NAME Recorded Feb 14, 2011
From: LA JOLLA CANCER RESEARCH FOUNDATION
To: THE BURNHAM INSTITUTE
Reel/Frame 025810/0286 →
Continuity (4)
Continuation 10285853 · Nov 1, 2002
Continuation 08625761 · Mar 29, 1996
Division 08066556 · May 26, 1993
Related Publication 20080102060A1 · May 1, 2008